董事长陈勇“回归”永安药业 被留置期间股价大涨控股股东拟减持

Core Viewpoint - Yong'an Pharmaceutical has resumed normal operations after the chairman's detention was lifted, despite previous management turmoil and a significant increase in stock price driven by rising taurine prices [1][2]. Company Overview - Yong'an Pharmaceutical, headquartered in Qianjiang, Hubei, specializes in taurine production, holding approximately 50% of the global market share with an annual production capacity of 58,000 tons [1]. - The company is a key supplier for major brands such as Red Bull, Nestlé, and Coca-Cola [1]. Management Changes - Chairman Chen Yong was previously detained for investigation by the Hekou County Supervisory Committee, with his son Chen Zidi temporarily taking over his responsibilities [1]. - Following the announcement of Chen Yong's detention, the company's stock price surged from 11.52 yuan on May 6 to 30.5 yuan by July 7 [1]. Market Dynamics - The increase in stock price is attributed to a rise in taurine prices, influenced by new FDA regulations requiring taurine in infant formula and pet food [2]. - Taurine prices rose from 14,250 yuan per ton in early April to as high as 25,000 yuan per ton by late April [2]. Production Expansion Plans - Despite the favorable market conditions, Yong'an Pharmaceutical has slowed down the construction of a previously approved 40,000-ton taurine production project, opting for phased development due to recent price declines [3]. - The company plans to complete the first phase of the project, which has already achieved production capacity, while the second phase will focus on additional facility upgrades [3]. Shareholder Actions - On July 24, amid ongoing uncertainties regarding the chairman's situation, the controlling shareholder, Huanggang Yong'an, announced a plan to reduce its stake in the company [4]. - Huanggang Yong'an holds 10,529,232 shares, representing 3.64% of the total share capital, and plans to sell up to 2,632,300 shares, or 0.91% of the total share capital [4].